Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EnBio HoldingsTSE:6092 +1.11%58 Altman Z-Score is 1.57 as of Jul. 17, 2026, which is 12% above its 10-year median of 1.40. GuruFocus rates TSE:6092 with a GF Score™ of 58/100 and a GF Value™ of 円799.37 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,063 Business Services companies, EnBio Holdings ranks worse than 74.13% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.56 is in distress zone. This implies bankruptcy possibility in the next two years.
EnBio Holdings has a Altman Z-Score of 1.57, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for EnBio Holdings's Altman Z-Score or its related term are showing as below:
TSE:6092'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.93 Med: 1.4 Max: 1.58
Current: 1.56
During the past 13 years, EnBio Holdings's highest Altman Z-Score was 1.58. The lowest was 0.93. And the median was 1.40.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
EnBio Holdings Altman Z-Score Related Terms
EnBio Holdings Altman Z-Score Historical Data
* Premium members only.
The historical data trend for EnBio Holdings's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6092 vs CTAS, CPRT, ULS: Altman Z-Score Comparison
For the Specialty Business Services subindustry, EnBio Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EnBio Holdings Altman Z-Score vs Business Services Industry
For the Business Services industry and Industrials sector, EnBio Holdings's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where EnBio Holdings's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
EnBio Holdings's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.2725
+
1.4
*
0.19
+
3.3
*
0.0479
+
0.6
*
0.437
+
1.0
*
0.5528
=
1.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
EnBio Holdings (TSE:6092) has a Altman Z-Score of 1.57 as of Jul. 17, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on EnBio Holdings and its competitors. This is 12% above median its historical median of 1.40. Over the past decade, EnBio Holdings' Altman Z-Score has ranged from 0.93 to 1.58. According to the industry distribution chart, EnBio Holdings ranks #788 out of 1063 companies in the Business Services industry, placing it in the top 74.1%.
Is EnBio Holdings' Altman Z-Score too high?
EnBio Holdings' current Altman Z-Score of 1.57 is 12% above median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 1.58. The Business Services industry median Altman Z-Score is 2.99. EnBio Holdings' value of 1.57 is 47.5% below this industry median. Based on the distribution chart, EnBio Holdings ranks #788 out of 1063 companies in the Business Services industry, which is below the industry midpoint. Overall, EnBio Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EnBio Holdings' Altman Z-Score compare to CTAS and CPRT?
According to the Business Services industry distribution chart, EnBio Holdings ranks #788 out of 1063 companies for Altman Z-Score. This places EnBio Holdings in the lower half of its industry. The industry median Altman Z-Score is 2.99. EnBio Holdings' value of 1.57 is 47.5% below this benchmark. Historically, EnBio Holdings' own Altman Z-Score has ranged from 0.93 to 1.58 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 2.99, EnBio Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Business Services company?
The median Altman Z-Score among Business Services companies is 2.99, based on 1,063 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EnBio Holdings's current Altman Z-Score of 1.57 is 47.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on EnBio Holdings and its competitors. For the Business Services industry, the median Altman Z-Score is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EnBio Holdings's current Altman Z-Score is 1.57, which is 12% above median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EnBio Holdings stock overvalued right now?
Based on GuruFocus' analysis, EnBio Holdings (TSE:6092) is currently considered Fairly Valued. The stock's GF Value™ is 円799.37, compared to a current price of 円728.00 — trading 8.9% below its estimated fair value. The current Altman Z-Score is 1.57, which is 12% above median its 10-year median of 1.40 and 47.5% below the Business Services industry median of 2.99. EnBio Holdings' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For EnBio Holdings (TSE:6092), the current Altman Z-Score is 1.57 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EnBio Holdings (TSE:6092) Overvalued in 2026?
Based on GuruFocus' analysis, EnBio Holdings stock appears to be undervalued.
The current stock price of 円728.00 is trading 8.9% below its estimated GF Value™ of 円799.37.
GuruFocus considers EnBio Holdings to be Fairly Valued.
Key valuation signals for TSE:6092:
Altman Z-Score: 1.57 (12% above median its 10-year median of 1.40)
GF Value™: 円799.37 vs. price of 円728.00 (8.9% below fair value)
Industry Position: 47.5% below the Business Services median (#788 of 1063)
No single metric tells the full story. See the TSE:6092 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EnBio Holdings Inc is a Japanese company engaged in environmental solution business, tools and chemicals business, and brownfield revitalization business. The environmental business involves investigation, remediation and risk management consulting of contaminated soil and groundwater; Tools and chemicals business involves sales of chemicals used for environmental work such as site investigation and remediation; and brownfield revitalization business which involves purchasing and regeneration of brownfields. The objective of the company is solving soil and groundwater contamination issues.
58GF Score
Get the complete analysis for TSE:6092
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6092 has been successfully added to your 
